Abstracts tagged "Rheumatoid arthritis (RA)"

Abstract Number: 455 • 2019 ACR/ARP Annual Meeting
Anti-Protein-Arginine Deiminase (PAD) 4 IgA Are Present in the Sera of Rheumatoid Arthritis Patients and Are Associated with Joint Erosion and Biological Treatment Use
Laura Martinez-Prat¹, Victor Manuel Martínez Taboada ², Marcos Lopez-Hoyos ³ and Michael Mahler ⁴, ¹Inova Diagnostics, Francisco de Vitoria University, San Diego, CA, ²Hospital Universitario Marqués de Valdecilla, Santander, Spain, ³Hospital Universitario Marqués de Valdecilla-IDIVAL, Santander, Cantabria, Spain, ⁴Inova Diagnostics, San Diego, CA
Background/Purpose: Over the past years, novel biomarkers have been described in rheumatoid arthritis (RA) patients, including autoantibodies to the protein-arginine deiminase (PAD) enzymes. Anti-PAD4 IgG…
Abstract Number: 494 • 2019 ACR/ARP Annual Meeting
Clinical and Biomarker Factor Associations with Symptoms and Future Development of RA: TIP-RA Collective
Kevin Deane¹, Sunil Nagpal ², V. Michael Holers ³, Gary Firestein ⁴, David Boyle ⁵, Jennifer Seifert ³, Jane Buckner ⁶, Eddie James ⁶, Laurakay Moss ⁷, Saman Barzideh ⁷, Sylvia Posso ⁶, William Robinson ⁸, Kristen Polinski ⁷, Roger Gilmore ⁷, Frédéric Baribaud ⁹, Navin Rao ² and George Vratsanos ¹⁰, ¹University of Colorado Denver, Division of Rheumatology, Aurora, CO, USA, Aurora, CO, ²Janssen R&D, Spring House, PA, ³University of Colorado Denver, Division of Rheumatology, Aurora, CO, USA, Denver, ⁴University of California, San Diego, San Diego, ⁵University of California, San Diego, San Diego, CA, ⁶Benaroya Research Institute, Seattle, WA, ⁷University of Colorado Denver, Aurora, CO, ⁸Stanford University, Palo Alto, CA, ⁹Janssen Research & Development, LLC, Spring House, PA, ¹⁰JNJ, Raritan, NJ
Background/Purpose: The Targeting Immune Responses for Prevention of RA (TIP-RA) Collaborative prospectively studies individuals at high risk for developing RA because of serum ACPA positivity…
Abstract Number: 537 • 2019 ACR/ARP Annual Meeting
Efficacy and Safety Results from a Randomized Double-Blind Study That Compared the Proposed Biosimilar ABP 798 with Rituximab in Subjects with Moderate to Severe RA
Gerd Burmester¹, Edit Drescher ², Pawel Hrycaj ³, David Chien ⁴, Zhiying Pan ⁴ and Stanley Cohen ⁵, ¹Charité—University Medicine Berlin, Berlin, Germany, ²2Veszprém Csolnoky Ferenc County Hospital, Veszprém, Hungary, ³Koscian Municipal Hospital, Koscian, Poland, ⁴Amgen, Thousand Oaks, CA, ⁵Metroplex Clinical Research Center, Dallas, TX
Background/Purpose: ABP 798 is being developed as a biosimilar to rituximab, a CD20-directed cytolytic antibody that is approved in the US and EU for treatment…
Abstract Number: 842 • 2019 ACR/ARP Annual Meeting
Mortality Ratio and Risk Factors in CT Confirmed Rheumatoid Arthritis Related Lung Disease: UIP, Pleural Effusion and the Time of Diagnosis of Rheumatoid Arthritis – Lung Disease
Mustafa Ekici ¹, Alper Sarı ², Yusuf Baytar ³, Ertugrul Cagri Bolek ², Berkan Armagan ⁴, Emre Bilgin ², Bayram Farisoğulları ², Omer Karadag ⁵, Ali İhsan Ertenli ², Sedat Kiraz ⁵, Şule Apras Bilgen ⁵, Levent Kilic ⁵, Ali Akdoğan ², Gamze durhan ³, Macit arıyürek ³ and Umut Kalyoncu⁶, ¹Hacettepe University, Faculty of Medicine, Department of Internal Medicine, Ankara, Turkey, ²Hacettepe University Vasculitis Centre, Ankara, Turkey, Ankara, Turkey, ³Hacettepe University, Faculty of Medicine, Department of Radiology, Ankara, Turkey, ⁴Department of Internal Medicine, Hacettepe University, Faculty of Medicine, Ankara, Turkey., Ankara, Turkey, ⁵Hacettepe University, Faculty of Medicine, Department of Internal Medicine, Division of Rheumatology, ankara, Turkey, ⁶Hacettepe University Department of Rheumatology, Ankara, Turkey
Background/Purpose: The frequency of pulmonary involvement in rheumatoid arthritis varies between 7-35%. The most important cause of death in RA patients is lung disease in…
Abstract Number: 974 • 2019 ACR/ARP Annual Meeting
Bruton’s Tyrosine Kinase (BTK) Inhibitors and Autoimmune Disease: Making Sense of BTK Inhibitor Specificity Profiles and Recent Clinical Trial Successes and Failures
Garth Ringheim¹, Matthew Wampole ¹ and Kinsi Oberoi ¹, ¹Clarivate Analytics, Philadelphia, PA
Background/Purpose: Clinical development of BTK/Tec family kinase inhibitors for treating autoimmune diseases has lagged that of their successful application in oncology. The lack of selective…
Abstract Number: 1177 • 2019 ACR/ARP Annual Meeting
Near Infrared Indocyanine Green Imaging Reveals Altered Anatomy and Diminished Function in Lymphatic Vessels in the Hands of Rheumatoid Arthritis Patients During Flare
Richard Bell¹, Homaira Rahimi ², Alicia Lieberman ², Ronald Wood ², Edward Schwarz ³ and Christopher Ritchlin ⁴, ¹University of Rochester Medical Center, Rochester, NY, ²University of Rochester Medical Center, Rochester, ³University of Rochester, Rochester, NY, ⁴Division of Allergy, Immunology and Rheumatology, Center for Musculoskeletal Research, University of Rochester School of Medicine and Dentistry, Rochester, NY, USA, Rochester, NY
Background/Purpose: Near infrared (NIR) imaging of indocyanine green (ICG) in rheumatoid arthritis (RA) models identified abnormal lymphatic vessel (LV) function, which can be quantified as…
Abstract Number: 1345 • 2019 ACR/ARP Annual Meeting
Are There Differences in Efficacy and Safety of Biological Disease-modifying Antirheumatic Drugs Between Elderly-onset and Young-onset Rheumatoid Arthritis?
Sadao Jinno¹, Akira Onishi ², Kengo Akashi ², Motomu Hashimoto ³, Wataru Yamamoto ³, Koichi Murata ³, Tohru Takeuchi ⁴, Takuya Kotani ⁴, Yuichi Maeda ⁵, Kosuke Ebina ⁶, Yonsu Son ⁷, Hideki Amuro ⁷, Ryota Hara ⁸, Masanori Katayama ⁹, Jun Saegusa ² and Akio Morinobu ², ¹Department of Rheumatology and Clinical Immunology, Kobe University Graduate School of Medicine, Osaka, Japan, ²Department of Rheumatology and Clinical Immunology, Kobe University Graduate School of Medicine, Kobe, Japan, ³Department of Advanced Medicine for Rheumatic Diseases, Kyoto University Graduate School of Medicine, Kyoto, Japan, ⁴Department of Internal Medicine IV, Osaka Medical College, Osaka, Japan, ⁵Department of Respiratory Medicine and Clinical Immunology, Osaka University Graduate School of Medicine, Osaka, Japan, ⁶Department of Musculoskeletal Regenerative Medicine, Osaka University, Graduate School of Medicine, Osaka, Japan, ⁷First Department of Internal Medicine, Kansai Medical University, Osaka, Japan, ⁸The Center for Rheumatic Disease, Department of Orthopedic Surgery, Nara Medical University, Nara, Japan, ⁹Department of Rheumatology, Osaka Red Cross Hospital, Osaka, Japan
Background/Purpose: To compare efficacy and safety of biological disease-modifying antirheumatic drugs (bDMARDs) between elderly-onset rheumatoid arthritis (EORA) and young-onset rheumatoid arthritis (YORA) patients. Methods: Patients with…
Abstract Number: 1372 • 2019 ACR/ARP Annual Meeting
Adherence to Treatment with Intravenous Biological Agents in Patients with Rheumatoid Arthritis
Gisele Alejandra Luna¹, fernando dal Pra ², Emilce Schneeberger ³, Leonela Lysseth Macias Oviedo ⁴ and Gustavo Citera ⁵, ¹Instituto de Rehabilitación Psicofísica, Ciudad Autonoma de Buenos Aires, Ciudad Autonoma de Buenos Aires, Argentina, ²Instituto Rehabilitacion Psicofisica, CABA, Ciudad Autonoma de Buenos Aires, Argentina, ³Instituto de Rehabilitación Psicofísica, Buenos Aires, Argentina, ⁴Instituto de Rehabilitacion Psicofisica, CABA, Ciudad Autonoma de Buenos Aires, Argentina, ⁵Instituto de Rehabilitación Psicofísica, Ciudad Autónoma de Buenos Aires, Buenos Aires, Argentina
Background/Purpose: The adherence to the therapeutic regimen in patients with Rheumatoid Arthritis (RA) varies between 30 and 80%. Classically, it is mentioned that the adherence…
Abstract Number: 1408 • 2019 ACR/ARP Annual Meeting
Efficacy of Pharmacological Treatment in Rheumatoid Arthritis: A Systematic Literature Review Informing the 2019 Update of the EULAR Recommendations for Management of Rheumatoid Arthritis
Andreas Kerschbaumer¹, Alexandre Sepriano ², Josef Smolen ¹, Désirée van der Heijde ², Maxime Dougados ³, Ronald F Van Vollenhoven ⁴, Iain McInnes ⁵, Johannes Bijlsma ⁶, Gerd Burmester ⁷, Maarten de Wit ⁸, Louise Falzon ⁹ and Robert B.M. Landewé ¹⁰, ¹Medical University of Vienna, Vienna, Austria, ²Leiden University Medical Center, Leiden, Netherlands, ³Cochin Hospital, Paris, France, ⁴Amsterdam Rheumatology & Immunology Center, Amsterdam, Netherlands, ⁵Institute of Infection, Immunity & Inflammation, University of Glasgow, Glasgow, United Kingdom, ⁶UMC Utrecht, Department of Rheumatology & Clinical Immunology, Utrecht, The Netherlands, Utrecht, Netherlands, ⁷Charité—University Medicine Berlin, Berlin, Germany, ⁸Department of Medical Humanities, Amsterdam Public Health (APH), Amsterdam University Medical Centre, Amsterdam, Netherlands, ⁹Northwell Health, New York, ¹⁰Amsterdam University Medical Center, Amsterdam, Netherlands
Background/Purpose: Via a systematic literature review of contemporary efficacy data of pharmacological therapies in RA we sought to inform the 2019 update of the EULAR…
Abstract Number: 1440 • 2019 ACR/ARP Annual Meeting
Relationship Between Adalimumab Concentrations, Plasma Cytokines, Anti-drug Antibodies and Disease Activity in Rheumatoid Arthritis
Lisa Stamp¹, Paula Keating ², Christopher Frampton ³, Murray Barclay ³, Niamh Fanning ³, Melanie Millier ⁴, Paul Hessian ⁴ and John O'Donnell ⁵, ¹University of Otago, Christchurch, Christchurch, Canterbury, New Zealand, ²Canterbury Health Laboratories, Christchurch, New Zealand, ³University of Otago, Christchurch, Christchurch, New Zealand, ⁴University of Otago, Dunedin, New Zealand, ⁵Christchurch Hospital, Christchurch, New Zealand
Background/Purpose: Therapeutic drug monitoring (TDM) would be important if there was evidence to support the utility of measured drug concentrations in making changes to dose…
Abstract Number: 1889 • 2019 ACR/ARP Annual Meeting
Biomarkers of Clinical Relapse and Radiological Progression in Patients with Rheumatoid Arthritis in Remission: Observational Study of 5 Years of Follow-up
Julio Ramirez¹, Andrea Cuervo Aguilera ², Raquel Celis ³, Virginia Ruiz-Esquide ³, Raul Castellanos-Moreira ⁴, Jose Gomez-Puerta ⁵, Raimon Sanmarti ⁵ and Juan Cañete ⁵, ¹Hospital Clinic, Barcelona, Spain, Barcelona, Spain, ²Hospital Clínic Barcelona, Spain, Barcelona, Spain, ³Hospital Clínic, Barcelona, Spain, ⁴Rheumatology Department. Hospital Clínic Barcelona, Barcelona, Catalonia, Spain, ⁵Department of Rheumatology, Hospital Clínic, Barcelona, Barcelona, Spain
Background/Purpose: To search biomarkers of clinical relapse and radiological progression in patients with RA in clinical remissionMethods: RA patients in clinical remission (defined as DAS28-ESR…
Abstract Number: 2005 • 2019 ACR/ARP Annual Meeting
Circulating Mitochondrial Danger-Associated Molecular Patterns as Novel Biomarkers of Disease Activity and Inflammation in Rheumatoid Arthritis
Bhargavi Duvvuri¹ and Christian Lood ¹, ¹University of Washington, Seattle
Background/Purpose: Rheumatoid Arthritis (RA) is an autoimmune inflammatory disease causing erosive and disabling joint damage. We recently found that mitochondria are extruded upon formation of…
Abstract Number: 2163 • 2019 ACR/ARP Annual Meeting
Prevalence of Postoperative Anemia in Patients with Rheumatoid Arthritis and Psoriatic Arthritis Undergoing Total Knee Arthroplasty: A Study of National Inpatient Sample 2010-2014
Karan Jatwani ¹, Karan Chugh ², Bikramjit Bindra ³ and Shraddha Jatwani², ¹Mount Sinai West - St Luke’s Hospital, New York, ²St. Vincent Evansville, Evansville, ³Government Medical College & Hospital, Chandigarh, India
Background/Purpose: Total knee arthroplasty (TKA) is a valuable option for improving function and pain control in patients with end-stage arthritis, especially those with inflammatory arthritis…
Abstract Number: 2302 • 2019 ACR/ARP Annual Meeting
Comparison Between Fibromyalgia and Neuropathic Pain in Patients with Established Rheumatoid Arthritis
Yong Gil Hwang¹, Lei Zhu ¹ and Larry Moreland ¹, ¹University of Pittsburgh, PITTSBURGH, PA
Background/Purpose: Our objectives were (1) to identify similarities and differences of pain symptoms identified by fibromyalgia (FM) and neuropathic pain (NP) screening tool (2) to…
Abstract Number: 2323 • 2019 ACR/ARP Annual Meeting
The Association Between Disease Activity with Coronary Microvascular Dysfunction in Rheumatoid Arthritis
Sicong Huang ¹, Zeling He ¹, Daniel Solomon ², Elena Massarotti ³, Charlotte Golnik ¹, Thany Seyok ¹, Seth Brownmiller ⁴, Tianrun Cai ³, Nicole Yang ³, Laurel Campbell ³, Leanne Barrett ³, Courtney Bibbo ³, Kenneth Pariser ³, Derrick Todd ³, Marcy Bolster ⁴, Marcelo Di Carli ³ and Katherine Liao¹, ¹Brigham and Women's Hospital, Boston, MA, ²Brigham and Women´s Hospital, Div. of Rheumatology, Immunology and Allergy, Boston, MA, ³Brigham and Women's Hospital, Boston, ⁴Massachusetts General Hospital, Boston, MA
Background/Purpose: Inflammation accounts for much of the excess cardiovascular disease (CVD) in patients with rheumatoid arthritis (RA). We hypothesize that increased systemic inflammation leads to…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].